We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance to Develop Breast Cancer Vaccine

By Biotechdaily staff writers
Posted on 21 Nov 2003
A collaboration to develop a new breast cancer vaccine has been announced by Bavarian Nordic A/S (Copenhagen, Denmark;) and Pharmexa A/S (Horsholm, Denmark).

The companies will combine Bavarian Nordic's MV-BN vector technology with Pharmexa's HER-2 DNA AutoVac vaccine. More...
In a clinical trial with 27 breast cancer patients, Pharmexa's vaccine was found safe and induced a T-cell-based immune response in patients. This vaccine will be reformulated in Bavarian Nordic's MVA-BN vector. By using this vector as a delivery mechanism, the companies hope to provoke an even stronger immune response.

In yet another approach to evoke a stronger immune response, dendritic cells will be removed from a breast cancer patient, stimulated with HER-2 AutoVac MVA-BN and then reinjected into the patient. The companies expect that clinical trials can begin relatively quickly for both procedures.

"The MVA-BN vector is the safest and most thoroughly tested virus vector in the market,” said Peter Wulff, president and CEO of Bavarian Nordic. "In earlier clinical trials with the MVA-BN vector, it has been confirmed that MVA-BN has an ability to generate a strong immune response in patients with malignant melanoma.”





Related Links:
Bavarian Nordic
Pharmexa

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.